BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results

BridgeBio (BBIO) stock rose early Tuesday after the drugmaker's growth disorder treatment topped Wall Street's expectations in a Phase 2 study.

The biotech company tested a daily pill in patients with achondroplasia, a genetic disease that affects the limbs and spine. Achondroplasia is the most common cause of dwarfism.